CAMBRIDGE, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Spero has applied to list its common stock on The NASDAQ Global Market under the ticker symbol “SPRO.”
BofA Merrill Lynch, Cowen and Stifel will act as joint book-running managers for the proposed offering. Oppenheimer & Co. will act as a co-manager.
About Spero
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections.
